Join us for one of the most important conversations happening in biotech today with leaders from China and the West.
DATES
26–28 OCT 2026
SITE
SHANGHAI, CHINA
CHINA ⇄ EUROPE ⇄ THE UNITED STATES ◆ ACCELERATING MEDICINE BEYOND BORDERS ◆ AI ⇄ AUTOMATION IN BIOTECH ◆ CHINA ⇄ EUROPE ⇄ THE UNITED STATES ◆ ACCELERATING MEDICINE BEYOND BORDERS ◆ AI ⇄ AUTOMATION IN BIOTECH ◆
01 – OVERVIEW
Bridging two great biotech ecosystems to catalyze breakthrough medicine.
~500
SENIOR LEADERS, BY INVITATION ONLY
02
ECOSYSTEMS: CHINA AND WEST
01
SHARED MISSION: ACCELERATE DRUG DISCOVERY AND ACCESS TO BREAKTHROUGH TREATMENT
Registration, coffee and app check-inBadge pickup and a nudge to confirm your booked 1:1s in the app before the day starts.
9:15
Lantern's opening remarks: what to expect, and how to navigate the next two days, including the Deal Room.
9:30
The thesis: how did China become the source of a $130B+ out-licensing wave? What does that mean for Western founders, buyers, and investors?
10:00
A candid sit-down with a senior Chinese biopharma leader: where is the real opportunity, and the real friction for cross-border partners over the next 2 years?
10:30
A field guide to the map: industrial parks like BioBay, shared lab spaces such as ATLATL. Where and how does a Western team plug in?
11:00
Coffee
11:30
Founders panel on real cross-border deals: what worked, what didn't?
12:15
Lunch, free-flowNo assigned tables. Open networking with the Deal Room running alongside.
13:30
From Pre-clinical, IIT to Phase 3, why do Chinese trials move faster? How far does that data travel with global regulators? This is the anchor session for anyone building a clinical asset.
14:30
Section 181, cross-border data rules, and tightening US regulation: what they actually mean for a deal.
15:05
Coffee
15:30
Wet-lab automation and bio foundation models are rewiring discovery. Which tools travel across the border, and who captures the value?
16:15
China-originated science is coming of age: late-stage ADCs and antibodies alongside a new wave of early startups. What is genuinely differentiated versus fast-follow?
17:00
Overflow 1:1s and follow-ups for anyone who wants more meetings before dinner.
Co-founder of age1, an early-stage venture firm backing founders in longevity and aging biotechnology.
Founder and CEO of Glyphic Biotechnologies, building a single-molecule protein sequencing platform to read proteins directly, at the resolution and scale that next-generation sequencing brought to DNA. He previously co-founded Nephrosant, whose noninvasive kidney-transplant rejection test is now available nationwide and reimbursed by Medicare.
Co-founder of Autonomy Bio, which is developing the first drugs that target human aging itself.
General Partner at Fundomo, where she focuses on deep tech and the life sciences. She competed six times in the International Science Olympiads, entered MIT as the first Armenian woman admitted, and is completing a PhD in Biophysics at Stanford.
05 – HOSTS
Mia Deng
Gokhan Er
Pamir Gelenbe
Julien Song Bell
06 – PRICING
2 registration tiers, set by role. Rates step up after September 28th.
Founders
General Admission$1,500
Late AdmissionFROM 28 SEP$2,200
VCs, Pharma & Service Providers
General Admission$3,500
Late AdmissionFROM 28 SEP$4,500
ADD-ON · DAY 03
Suzhou BioBAY Field Trip
A day at the BioBAY park and a classical Suzhou garden. We take you out of central Shanghai in the morning and bring you back before dinner.
First come, first served. 150 places.
$300PER PERSON
All rates in USD. Late registration opens 28 September 2026.
